PRECISION MEDICINE
Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma
Jun
2014
Vol. 33. No. 2
Key molecular and immunological insights over the past
decade have radically changed the face of therapy in
melanoma. Whereas 5 years ago, treatment for advanced
melanoma was restricted to the alkylating agent dacarbazine
and the immunostimulants interleukin-2 and
interferon-a-2b, today the therapeutic menu includes precise
therapies that target key determinants in oncogenic
pathways and immune checkpoints. In this chapter, we will
review the current status and future directions of targeted
therapies for melanoma directed at mitogen-activated
pathways and immune checkpoints.
Semin Cutan Med Surg 33:60-67 © 2014 Frontline Medical
Communications
PURCHASE NOW